Citations

Clear

904 citation(s) found for "Gordon, S".

Sinus Venosus Atrial Septal Defect
Jost, Christine H. Attenhofer , Connolly, Heidi M. , Danielson, Gordon K., Bailey, Kent R. , Schaff, Hartzell V. , Shen, Win‐Kuang , Warnes, Carole A. , Seward, James B., Puga, Francisco J., Tajik, A. Jamil , Schaff, Hartzell

Mayo Clinic

Circulation | September 20, 2005 | Volume: 112 | Issue: 13 | Pages: 1953-1958

10.1161/circulationaha.104.493775 | PMID 16172274 Get It

Background— Sinus venosus atrial septal defect (SVASD) differs from secundum atrial septal defect by its atrial septal location and its association with anomalous pulmonary venous connection (APVC). Data on long-term outcome after surgical repair are limited. Methods and Results— We reviewed outcomes of 115 patients (mean age±SD 34±23 years) with SVASD who had repair from 1972 through 1996. APVC was present in 112 patients (97%). Early mortality was 0.9%. Complete follow-up was obtained for 108 patients (95%) at 144±99 months. Symptomatic improvement was noted in 83 patients (77%), and deterioration was noted in 17 patients (16%). At follow-up, 7 (6%) of 108 patients had sinus node dysfunction, a permanent pacemaker, or both, and 15 (14%) of 108 patients had atrial fibrillation. Older age at repair was predictive of postoperative atrial fibrillation ( P =0.033). No reoperations were required during follow-up. Survival was not different from expected for an age- and sex-matched population. Clinical improvement was more common with older age at surgery ( P =0.014). Older age at repair ( P =0.008) and preoperative New York Heart Association class III or IV ( P =0.038) were independent predictors of late mortality. Conclusions— Operation for SVASD is associated with low morbidity and mortality, and postoperative subjective clinical improvement occurs irrespective of age at surgery. Postoperative atrial fibrillation appears to be related to older age at operation. SVASD repair achieves survival similar to that of a matched population and should be considered whenever repair may impact survival or symptoms.
Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
Dewald, Gordon W., Therneau, Terry M. , Lee, You Kyoung , Fink, Stephanie, Smoley, Stephanie A., Paternoster, Sarah F., Adeyinka, Adewale, Ketterling, Rhett P. , Dyke, Daniel L. Van , Fonseca, Rafaël , Kyle, Robert A. , Larson, Dirk R. , Ketterling, Rhett P , Fonseca, Rafael

Mayo Clinic

Blood | July 20, 2005 | Volume: 106 | Issue: 10 | Pages: 3553-3558

10.1182/blood-2005-05-1981 | PMID 16030187 Get It

AbstractThe clinical efficacy of evaluating genetic anomalies in metaphase cells versus interphase nuclei for multiple myeloma (MM) is poorly understood. Therefore, survival for 154 patients with newly diagnosed untreated MM was compared with results from analysis of metaphase and interphase cells. Metaphases were studied by conventional cytogenetics and fluorescent-labeled DNA probes (fluorescence in situ hybridization [FISH]), whereas inter-phase nuclei were evaluated only by FISH. All FISH studies were done using DNA probes to detect t(4;14)(p16;q32), t(11;14)(q13;q32), t(14;16)(q32;q23), del(17) (p13.1), and chromosome 13 anomalies. Metaphases were abnormal by cytogenetics and/or metaphase FISH in 61 (40%) patients. Abnormal interphase nuclei were observed in 133 (86%) patients, including each patient with abnormal metaphases. FISH was a necessary adjunct to cytogenetics to detect t(4;14) and t(14;16) in metaphase cells. Patient survival was especially poor for patients with greater than 50% abnormal interphase nuclei, although this result was more likely due to level of plasma cells than specific chromosome anomalies. For metaphase data, patients with t(4;14), t(14;16), del(17) (p13.1), and/or chromosome 13 anomalies (primarily monosomy 13) had poor survival. A different outcome was observed for interphase data as patients with t(4;14) or t(14;16) had poor survival, whereas patients with chromosome 13 anomalies had intermediate survival: interphase FISH did not substitute for metaphase analysis.
Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma
Czuczman, Myron S., Thall, Aron D., Younes, Anas , Emmanouilides, Christos, Miller, Thomas P. , Moore, Joseph O., Leonard, John P. , Gordon, Leo I. , Sweetenham, John , Alkuzweny, Baha, Finucane, Deborah M., Leigh, Bryan R., Witzig, Thomas E. , Vose, Julie M. , Gordon, Leo I

Mayo Clinic

Journal of Clinical Oncology | June 30, 2005 | Volume: 23 | Issue: 19 | Pages: 4390-4398

10.1200/jco.2005.09.018 | PMID 15994148 Get It

PurposeThis multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with relapsed or refractory follicular lymphoma.Patients and MethodsPatients had follicular lymphoma that had relapsed or failed to respond to primary therapy; the majority (90%) presented with stage III or IV disease. Four weekly intravenous infusions of galiximab were administered at doses of 125, 250, 375, or 500 mg/m2.ResultsThirty-seven patients received galiximab treatment and were evaluated for safety; 35 were assessable for response. Antibody infusions were safe and well tolerated with no dose-limiting toxicities. A total of 22 (60%) of 37 patients experienced adverse events related to galiximab. All but one of the events were grade 1 or 2; the most common were fatigue, nausea, and headache. Cytopenias were rare; only one patient experienced anemia and febrile neutropenia, which were unrelated to galiximab and resolved after treatment. No patient developed antigaliximab antibody formation. The mean serum half-life ranged from 13 to 24 days. The overall response rate was 11% (two complete responses and two partial responses). Time to best response was delayed (months 3, 6, 9, and 12). Twelve patients (34%) maintained stable disease. Nearly half of all patients (49%) had a decrease in indicator lesions. Two responders remain on study without progression (22 and 24.4 months).ConclusionThe favorable safety profile of galiximab and evidence of single-agent biologic activity and dose-dependent pharmacokinetics support further evaluation of galiximab as a treatment for follicular lymphoma, possibly in combination with other lymphoma therapies.
Mycophenolate mofetil combination therapy improves long‐term outcomes after liver transplantation in patients with and without hepatitis C
Wiesner, Russell H., Shorr, Jolene, Steffen, Bettina J., Chu, Alice , Gordon, Robert D., Lake, John R.

Mayo Clinic

Liver Transplantation | June 22, 2005 | Volume: 11 | Issue: 7 | Pages: 750-759

10.1002/lt.20453 | PMID 15973716 Get It

Self-Induced Hypoglycemia: A Review of Psychiatric Aspects and Report of Three Cases
Moore, Gordon L., McBurney, P. Louis, Service, F. John

Mayo Clinic

Psychiatry in Medicine | May 3, 2005 | Volume: 4 | Issue: 3 | Pages: 301-311

10.2190/2w0q-hfjt-233q-95jr | PMID 4742687 Get It

Unauthorized self-administration of hypoglycemic agents produces a unique clinical situation. Because the symptoms and laboratory findings are consistent with a functioning adenoma of the pancreas, there is a significant hazard of unnecessary surgery. By appropriate laboratory tests, however, the alert physician may be able to justify suspicion that the disorder is self-induced. Accurate diagnosis may be further facilitated by recognizing certain similarities in these patients. Review of published reports and study of three cases newly presented have revealed these characteristics with enough consistency for proposal of a psychiatric syndrome. In hypoglycemia, factitial causation is suggested by the combination of female sex, single status, medical knowledge derived from experience as a diabetic or from vocational or family contacts, and features of the hysterical personality.
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes
Steensma, David P. , Dewald, Gordon W., Powell, Heather L., McClure, Rebecca F., Levine, Ross L. , Gilliland, D. Gary, Tefferi, Ayalew , Lasho, Terra L. , Steensma, David P

Mayo Clinic

Blood | April 29, 2005 | Volume: 106 | Issue: 4 | Pages: 1207-1209

10.1182/blood-2005-03-1183 | PMID 15860661 Get It

AbstractA somatic mutation in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently described in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. The prevalence of this mutation in either “atypical” myeloproliferative disorders (MPDs) or the myelodysplastic syndromes (MDSs) is unknown. Bone marrow–derived genomic DNA from 245 patients—119 with chronic myelomonocytic leukemia (CMML), 101 with MDS, 11 with hypereosinophilic syndrome (HES), 8 with systemic mastocytosis (SM), and 6 with chronic neutrophilic leukemia (CNL)—was screened for the JAK2 V617F mutation. A mutant allele was detected in 11 patients: 3 with CMML (3%), 5 with MDS (5%), 2 with SM, and 1 with CNL. Interestingly, one of the patients with SM and the patient with CNL with JAK2 V617F had a history of lymphoma, and this patient with SM also had associated myelofibrosis and CMML. The current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders.
Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia
Schilder, Russell J., Molina, Arturo , Bartlett, Nancy L. , Gordon, Leo I. , Murray, James L. , Spies, Stewart, Wiseman, Gregory A., Witzig, Thomas E. , Wang, Hua , White, Christine A. , Gordon, Leo I , Bartlett, Nancy L

Mayo Clinic

Cancer Biotherapy and Radiopharmaceuticals | October 22, 2004 | Volume: 19 | Issue: 4 | Pages: 478-481

10.1089/cbr.2004.19.478 | PMID 15453962 Get It

Duplication of 7p: Further delineation of the phenotype and restriction of the critical region to the distal part of the short arm
Berry, Susan A. , Dewald, Gordon W., King, Richard A. , Reish, Orit

Mayo Clinic

American Journal of Medical Genetics | October 20, 2004 | Volume: 61 | Issue: 1 | Pages: 21-25

10.1002/(sici)1096-8628(19960102)61:1<21::aid-ajmg4>3.0.co;2-# | PMID 8741912 Get It

Surgery for Aneurysms of the Aortic Root
Zehr, Kenton J., Orszulak, Thomas A., Mullany, Charles J., Matloobi, Alireza, Daly, Richard C. , Sundt, Thoralf M. , Puga, Francisco J., Danielson, Gordon K., Schaff, Hartzell V. , Dearani, Joseph A. , Schaff, Hartzell

Mayo Clinic

Circulation | August 17, 2004 | Volume: 110 | Issue: 11 | Pages: 1364-1371

10.1161/01.cir.0000141593.05085.87 | PMID 15313937 Get It

Background— This study evaluated long-term results of aortic root replacement and valve-preserving aortic root reconstruction for patients with aneurysms involving the aortic root. Methods and Results— Two-hundred three patients aged 53±16 years (mean±SD; 153 male, 50 female) underwent elective or urgent aortic root surgery from 1971 to 2000 for an aortic root aneurysm: 149 patients underwent a composite valve conduit reconstruction, and 54 patients underwent valve-preserving aortic root reconstruction. Fifty patients had Marfan syndrome. In-hospital and 30-day mortality was 4.0% (8/203) overall: for a composite valve conduit procedure, the corresponding value was 4.0% (6/149) and for valve-preserving procedure, 3.7% (2/54) ( P =NS). Morbidity included 3 strokes (1%), 10 perioperative myocardial infarctions (5%), and 8 reoperations for bleeding (4%). Actuarial survival at 5, 10, 15, and 20 years was 93% (95% confidence interval [CI] = 88% to 97%), 79% (95% CI = 71% to 87%), 67% (95% CI = 57% to 79%), and 52% (95% CI = 36% to 69%), respectively. Freedom from reoperation was 72% (95% CI = 54% to 86%) at 20 years. Complications with anticoagulation occurred in 29 patients; with valve thrombosis, in 2; and with hemorrhage, in 27 (4 life threatening and 23 minor). Freedom from thromboembolism was 91% (95% CI = 77% to 98%) at 20 years. Freedom from endocarditis was 99% (95% CI = 92% to 100%) at 20 years. Multivariate analysis revealed preoperative mitral valve regurgitation (+3 to 4) and older age to be significant predictors of late death ( P ≤0.005), and Marfan syndrome, initial valve-preserving aortic root reconstruction, and need for a concomitant procedure at initial operation to be significant predictors of the need for reoperation ( P ≤0.01). Conclusions— Aortic root replacement for aortic root aneurysms can be done with low morbidity and mortality. Composite valve conduit reconstruction resulted in a durable result. There were few serious complications related to the need for long-term anticoagulation or a prosthetic valve. Reoperation was most commonly required because of failure of the aortic valve when a valve-preserving aortic root reconstruction was performed or for other cardiac or aortic disease elsewhere.
Surgical Treatment of Craniosynostosis: Outcome Analysis of 250 Consecutive Patients
Sloan, Gerald M., Wells, K, Raffel, Corey , McComb, J. Gordon

Mayo Clinic

Pediatrics | August 13, 2004 | Volume: 100 | Issue: 1 | Pages: e2-e2

10.1542/peds.100.1.e2 | PMID 9200376 Get It

Objective. Surgery for craniosynostosis has evolved rapidly over the past two decades, with increased emphasis on early, extensive operations. Older published series may not accurately reflect more recent experience. Our study was designed to analyze outcome in a large series of consecutive patients treated recently at a single center.Methods. We reviewed 250 consecutive patients who underwent surgical treatment of craniosynostosis between January 1, 1987 and December 31, 1992. They were divided into nine groups by suture involvement: sagittal, unilateral coronal, bilateral coronal, unilateral lambdoid, bilateral lambdoid, metopic, multiple suture, the Klee-blattschädel deformity (cloverleaf skull), and acquired craniosynostosis. Outcome was analyzed in terms of residual deformities and irregularities, complications, mortality, as well as the need for additional surgery.Results. There were 157 males (62.8%) and 93 females (37.2%), with most of the male preponderance accounted for by the large sagittal synostosis group, which consisted of 82 males and 25 females. Median age at first operation was 147 days. A named syndrome was present in 23 patients (9.2%) and was more common than expected with bilateral and unilateral coronal synostosis, the Kleeblattschädel deformity, and multiple suture synostosis. There were two deaths (0.8%), both with Klee-blattschädel patients, and 17 other complications (6.8%). Morbidity and mortality were significantly associated with secondary vs primary operations and syndromic vs nonsyndromic patients. Outcome analysis revealed the best surgical results with metopic synostosis and significantly less good results with the Kleeblattschädel deformity, multiple suture synostosis, and bilateral coronal synostosis.Conclusions. Using modern surgical techniques, craniosynostosis can be corrected with good outcomes and relatively low morbidity and mortality, particularly for otherwise healthy, nonsyndromic infants.